MUMBAI, India, Nov. 14 -- Intellectual Property India has published a patent application (202517097109 A) filed by Xenothera, Nantes, France, on Oct. 8, for 'combination of antibodies, or antigen-binding fragments thereof, for the treatment of cancer and composition thereof.'
Inventor(s) include Bassissi, Firas; Ciron, Carine; Duvaux, Odile; and Vanhove, Bernard.
The application for the patent was published on Nov. 14, under issue no. 46/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to a combination of antibodies, or antigen-binding fragments thereof, for use in the treatment of a cancer in a human subject in need thereof, the combination comprising at least a first antibody, or an antigen-binding fragment thereof, at least a second antibody, or an antigen-binding fragment thereof, and at least a third antibody, or an antigen-binding fragment thereof, each of these antibodies independently and specifically binding to an antigen selected from the group consisting of SLC3A2, CKAP4, Annexin A2, GSTO1, Annexin A5, MX1, RTN4, FASN and PDIA4. The present invention further relates to a pharmaceutical composition for use in the treatment of a cancer in a human subject in need thereof comprising this combination of antibodies, or antigen-binding fragments thereof and a pharmaceutically acceptable carrier."
The patent application was internationally filed on Mar. 22, 2024, under International application No.PCT/EP2024/057865.
Disclaimer: Curated by HT Syndication.
